Therapeutic Asset Ratings

130 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cyclophosphamide Head and Neck Squamous Cell Carcinoma	UNC Lineberger Comprehensive Cancer Center	P4	BB (66)
Epirubicin Head and Neck Squamous Cell Carcinoma	UNC Lineberger Comprehensive Cancer Center	P4	BB (66)
Pembrolizumab Head and Neck Squamous Cell Carcinoma	UNC Lineberger Comprehensive Cancer Center	P4	BB (66)
Cetuximab Head and Neck Squamous Cell Carcinoma	Fate Therapeutics	P3	B (62)
Docetaxel Head and Neck Squamous Cell Carcinoma	National Cancer Institute (NCI)	P3	B (62)
(+)-VINCRISTINE Head and Neck Squamous Cell Carcinoma	Neonc Technologies, Inc.	P2	B (61)
Durvalumab Head and Neck Squamous Cell Carcinoma	University Health Network, Toronto	P2	B (59)
Pyrotinib Head and Neck Squamous Cell Carcinoma	Indaptus Therapeutics, Inc	P2	B (59)
Nivolumab Head and Neck Squamous Cell Carcinoma	Fred Hutchinson Cancer Center	P2	B (58)
rc48-adc Head and Neck Squamous Cell Carcinoma	Indaptus Therapeutics, Inc	P2	B (58)
Tislelizumab Head and Neck Squamous Cell Carcinoma	Indaptus Therapeutics, Inc	P2	B (58)
Eloxatin Head and Neck Squamous Cell Carcinoma	Arcus Biosciences, Inc.	P2	B (57)
Toripalimab Head and Neck Squamous Cell Carcinoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	P3	B (56)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Head and Neck Squamous Cell Carcinoma	OncoNano Medicine, Inc.	P2	B (56)
Polyiclc Head and Neck Squamous Cell Carcinoma	UNC Lineberger Comprehensive Cancer Center	P2	B (56)
PREDNISONE TABLETS Head and Neck Squamous Cell Carcinoma	MacroGenics	P2	CCC (55)
Regorafenib Head and Neck Squamous Cell Carcinoma	Neonc Technologies, Inc.	P2	CCC (55)
Atezolizumab Head and Neck Squamous Cell Carcinoma	National University Hospital, Singapore	P2	CCC (54)
Calcium folinate pentahydrate Head and Neck Squamous Cell Carcinoma	Neonc Technologies, Inc.	P1/2	CCC (53)
Adebrelimab Head and Neck Squamous Cell Carcinoma	Hansoh BioMedical R&D Company	P2	CCC (52)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Head and Neck Squamous Cell Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (52)
Belapectin Head and Neck Squamous Cell Carcinoma	Providence Health & Services	P2	CCC (51)
io102-io103 Head and Neck Squamous Cell Carcinoma	IO Biotech	P2	CCC (51)
Avelumab Head and Neck Squamous Cell Carcinoma	TILT Biotherapeutics Ltd.	P2	CCC (50)
Recombinant Ephb4-Hsa Fusion Protein Head and Neck Squamous Cell Carcinoma	University of Southern California	P2	CCC (49)

Showing 1 to 25 of 130 assets

PreviousPage 1 of 6Next